These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 24133446)

  • 1. PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy.
    Orena S; Maurer TS; She L; Eudy R; Bernardo V; Dash D; Loria P; Banker ME; Tugnait M; Okerberg CV; Qian J; Boustany-Kari CM
    Front Pharmacol; 2013; 4():115. PubMed ID: 24133446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Non-Steroidal Mineralocorticoid Receptor Antagonist KBP-5074 Limits Albuminuria and has Improved Therapeutic Index Compared With Eplerenone in a Rat Model With Mineralocorticoid-Induced Renal Injury.
    Jaisser F; Tan X; Chi S; Liu J; Wang P; Bush M; Benn V; Yang YF; Zhang J
    Front Pharmacol; 2021; 12():604928. PubMed ID: 34248613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism.
    Eudy RJ; Sahasrabudhe V; Sweeney K; Tugnait M; King-Ahmad A; Near K; Loria P; Banker ME; Piotrowski DW; Boustany-Kari CM
    J Transl Med; 2011 Oct; 9():180. PubMed ID: 22017794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion.
    Bamberg K; Johansson U; Edman K; William-Olsson L; Myhre S; Gunnarsson A; Geschwindner S; Aagaard A; Björnson Granqvist A; Jaisser F; Huang Y; Granberg KL; Jansson-Löfmark R; Hartleib-Geschwindner J
    PLoS One; 2018; 13(2):e0193380. PubMed ID: 29474466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
    Epstein M; Williams GH; Weinberger M; Lewin A; Krause S; Mukherjee R; Patni R; Beckerman B
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):940-51. PubMed ID: 17699311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.
    Arai K; Homma T; Morikawa Y; Ubukata N; Tsuruoka H; Aoki K; Ishikawa H; Mizuno M; Sada T
    Eur J Pharmacol; 2015 Aug; 761():226-34. PubMed ID: 26073023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of local aldosterone by eplerenone reduces renal structural damage in a novel model of chronic cyclosporine A nephrotoxicity.
    Sun QL; Li M; Rui HL; Chen YP
    J Renin Angiotensin Aldosterone Syst; 2015 Jun; 16(2):301-10. PubMed ID: 25500744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats.
    Arai K; Tsuruoka H; Homma T
    Eur J Pharmacol; 2015 Dec; 769():266-73. PubMed ID: 26607463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mineralocorticoid receptor blockade suppresses dietary salt-induced ACEI/ARB-resistant albuminuria in non-diabetic hypertension: a sub-analysis of evaluate study.
    Nishimoto M; Ohtsu H; Marumo T; Kawarazaki W; Ayuzawa N; Ueda K; Hirohama D; Kawakami-Mori F; Shibata S; Nagase M; Isshiki M; Oba S; Shimosawa T; Fujita T
    Hypertens Res; 2019 Apr; 42(4):514-521. PubMed ID: 30631161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial.
    Ando K; Ohtsu H; Uchida S; Kaname S; Arakawa Y; Fujita T;
    Lancet Diabetes Endocrinol; 2014 Dec; 2(12):944-53. PubMed ID: 25466242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel Aldosterone Antagonist Limits Renal Injury in 5/6 Nephrectomy.
    Fujihara CK; Kowala MC; Breyer MD; Sena CR; Rodrigues MV; Arias SCA; Fanelli C; Malheiros DM; Jadhav PK; Montrose-Rafizadeh C; Krieger JE; Zatz R
    Sci Rep; 2017 Aug; 7(1):7899. PubMed ID: 28801620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effect of eplerenone treatment in children with chronic allograft nephropathy.
    Baskin E; Siddiqui MA; Gülleroğlu K; Özdemir BH; Yılmaz AÇ; Çolak MY; Akdur A; Soy EA; Moray G; Haberal M
    Pediatr Transplant; 2023 Sep; 27(6):e14557. PubMed ID: 37283242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin II- and salt-induced kidney injury through Rac1-mediated mineralocorticoid receptor activation.
    Kawarazaki W; Nagase M; Yoshida S; Takeuchi M; Ishizawa K; Ayuzawa N; Ueda K; Fujita T
    J Am Soc Nephrol; 2012 Jun; 23(6):997-1007. PubMed ID: 22440899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of mineralocorticoid receptor/Rho/Rho-kinase pathway in obesity-related renal injury.
    Tokuyama H; Wakino S; Hara Y; Washida N; Fujimura K; Hosoya K; Yoshioka K; Hasegawa K; Minakuchi H; Homma K; Hayashi K; Itoh H
    Int J Obes (Lond); 2012 Aug; 36(8):1062-71. PubMed ID: 22184057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects.
    Ménard J; Rigel DF; Watson C; Jeng AY; Fu F; Beil M; Liu J; Chen W; Hu CW; Leung-Chu J; LaSala D; Liang G; Rebello S; Zhang Y; Dole WP
    J Transl Med; 2014 Dec; 12():340. PubMed ID: 25491597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of mineralocorticoid receptor blockade on glucocorticoid-induced renal injury in adrenalectomized rats.
    Rafiq K; Nakano D; Ihara G; Hitomi H; Fujisawa Y; Ohashi N; Kobori H; Nagai Y; Kiyomoto H; Kohno M; Nishiyama A
    J Hypertens; 2011 Feb; 29(2):290-8. PubMed ID: 21243738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats.
    Blasi ER; Rocha R; Rudolph AE; Blomme EA; Polly ML; McMahon EG
    Kidney Int; 2003 May; 63(5):1791-800. PubMed ID: 12675855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An additive effect of eplerenone to ACE inhibitor on slowing the progression of diabetic nephropathy in the db/db mice.
    Zhou G; Johansson U; Peng XR; Bamberg K; Huang Y
    Am J Transl Res; 2016; 8(3):1339-54. PubMed ID: 27186263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The selective mineralocorticoid receptor modulator AZD9977 reveals differences in mineralocorticoid effects of aldosterone and fludrocortisone.
    Bamberg K; William-Olsson L; Johansson U; Jansson-Löfmark R; Hartleib-Geschwindner J
    J Renin Angiotensin Aldosterone Syst; 2019; 20(1):1470320319827449. PubMed ID: 30813831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress.
    Nagase M; Matsui H; Shibata S; Gotoda T; Fujita T
    Hypertension; 2007 Nov; 50(5):877-83. PubMed ID: 17875821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.